In this review, we will discuss data implicating FAM83 members in the aberrant activation of EGFR, MAPK, PI3K/AKT, and other cancer-associated signaling pathways and discuss their potential to serve as novel therapeutic targets. The gene discussed is AKT1; the disease is cancer.